Illumina, a global provider of DNA sequencing and array-based technologies, has joined the Worldwide Innovative Networking (WIN) Consortium. Founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of academic, industry, insurance and nonprofit research organizations working to make personalized cancer care a reality for patients worldwide.

“We are very pleased to welcome Illumina to WIN,” said Dr. John Mendelsohn, chairman of the WIN Consortium and the director of the Khalifa Institute for Personalized Cancer Therapy at MD Anderson Cancer Center. “Their expertise will be invaluable as we work to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials, the most promising advances in genomic-based cancer research.”

“The WIN Consortium is uniquely bringing together renowned institutions and cancer researchers from around the world. By working together, we will be able to generate the type of clinical utility data needed to define the value of next-generation genomic testing for oncology, as well as newer methods such as liquid biopsy,” said John Leite, vice president of Illumina’s Oncology business. “We look forward to collaborating, with the ultimate goal of making personalized therapy a reality for cancer patients.”